drugset / Trial / NCT01366365

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

NCT01366365

Phase 1 Completed 28 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This double-blind, randomized, two-cohort, placebo-controlled, parallel group study characterized the pharmacokinetics, safety, and tolerability of MNTX following single doses and at steady-state during multiple dosing and assessed the effects of aging on the pharmacokinetics, safety and tolerability of MNTX.

Timeline

Start
2006-10
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified Intravenous

Indications

No indication recorded.